News

Arphio is thrilled to announce the appointment of David Olafsson as their interim Chief Financial Officer. David Olafsson brings a wealth of financial expertise and strategic leadership to Arphio. With an illustrious career in the finance sector, Da...

Adalvo, in collaboration with Arphio, is proud to introduce Teduglutide, a groundbreaking treatment addressing the urgent unmet needs of patients with Short Bowel Syndrome (SBS). Short Bowel Syndrome is a rare disease characterized by the inability ...

Arphio is pleased to announce that we have partnered with UK based niche generics company Colonis to bring Rybrila, a rare indication drug to patients in need within several emerging market territories.  Rybrila is an asset indicated in the sym...

The story behind Arphio is an interesting one. Two leading pharmaceutical companies partnering with the mission to improve access to vital treatments to patients suffering from rare diseases. When selecting the name and visual identity the mission a...

Aztiq and SK Pharma are thrilled to announce the recent establishment of a new entity ArphioTM, a powerhouse, solely dedicated to orphan drugs with the intention of improving access to vital treatments, to patients suffering from rare diseases and wi...